Honasa (Mamaearth's parent) is a high-quality FMCG

is a high-quality FMCG turnaround now firing — Finkhoz rates it 8.69/10 overall, #1 of 20 in its peer group, with a perfect Outlook (10), Robust Track Record (8.93) and Reasonable valuation (8.75), the only soft spot being Medium Reliability (7.19) owing to its short listed history and the FY25 "Project Neev" distribution overhaul (which caused a ₹65 Cr write-off). The business has posted four straight quarters of 20%+ revenue growth, capped by Q1 FY27's record ₹90.5 Cr profit (+119% YoY) on ₹756 Cr revenue (+27%), with profit compounding well ahead of sales on operating leverage (margin +585 bps). Growth is broad-based — The Derma Co. crossed ₹1,000 Cr ARR, Mamaearth re-accelerated to high-teens, and offline reach hit 2.5 lakh+ outlets. The catch is a premium ~62x trailing P/E (vs ~44x segment) that leaves no room for a stumble. Net: a genuine growth compounder, but priced like one — not a value entry.